Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2023 07:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
November 06, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

Priority Review of resmetirom new drug application underway in the U.S.Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023$500 million financing provides Madrigal with funds to...
November 02, 2023 16:05 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
October 12, 2023 16:05 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
September 28, 2023 22:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
September 28, 2023 16:01 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Proposed Public Offering

CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
September 14, 2023 16:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
September 13, 2023 09:10 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
September 11, 2023 07:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
August 08, 2023 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug AdministrationNASH disease education and market development activities expand to support potential first-to-market launch in...